Sierra Oncology, Inc. (SRRA): Price and Financial Metrics


Sierra Oncology, Inc. (SRRA)

Today's Latest Price: $16.03 USD

0.02 (-0.12%)

Updated Jan 20 6:55pm

Add SRRA to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 484 in Biotech

See all "A" rated Strong Buy stocks

SRRA Stock Price Chart Interactive Chart >

Price chart for SRRA

SRRA Price/Volume Stats

Current price $16.03 52-week high $16.92
Prev. close $16.05 52-week low $8.55
Day low $15.73 Volume 15,400
Day high $16.36 Avg. volume 50,992
50-day MA $15.21 Dividend yield N/A
200-day MA $12.99 Market Cap 176.99M

Sierra Oncology, Inc. (SRRA) Company Bio


Sierra Oncology, Inc., formerly known as ProNAi Therapeutics, is a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNAi technology platform. The company was founded in 2003 and is based in Vancouver, Canada.


SRRA Latest News Stream


Event/Time News Detail
Loading, please wait...

SRRA Latest Social Stream


Loading social stream, please wait...

View Full SRRA Social Stream

Latest SRRA News From Around the Web

Below are the latest news stories about Sierra Oncology Inc that investors may wish to consider to help them evaluate SRRA as an investment opportunity.

We're Keeping An Eye On Sierra Oncology's (NASDAQ:SRRA) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | January 18, 2021

Sierra Oncology to Present at H.C. Wainwright 2021 BioConnect Virtual Conference

Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, today announced that President and Chief Executive Officer Stephen Dilly, MBBS, PhD, will present an overview of the company at the H.C. Wainwright 2021 BioConnect Virtual Conference taking place January 11-14, 2021.

Yahoo | January 5, 2021

Is SRRA A Good Stock To Buy Now?

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 817 13F filings submitted by hedge funds and prominent investors. These filings show these funds’ portfolio positions as of September 30th, 2020. […]

Yahoo | December 11, 2020

Sierra Oncology to Host KOL Panel Event to Discuss Updated Phase 3 Myelofibrosis Data Presented at ASH

\\--Sierra Chief Development Officer Barbara Klencke to be joined by renowned myelofibrosis experts Jean-Jacques Kiladjian, Ruben Mesa and Srdan Verstovsek--VANCOUVER, BC, Dec. 1, 2020 /CNW/ - Sierra Oncology, Inc.

Yahoo | December 1, 2020

Sierra Oncology Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company focused on the Phase 3 execution, registration and potential commercialization of momelotinib, a novel drug that may address serious unmet needs in myelofibrosis, granted a stock option to a new employee as approved by the Compensation Committee of the Company's Board of Directors, under Sierra Oncology's 2018 Equity Inducement Plan.

Yahoo | November 25, 2020

Read More 'SRRA' Stories Here

SRRA Price Returns

1-mo -1.78%
3-mo 25.73%
6-mo 22.46%
1-year 15.26%
3-year -87.55%
5-year -95.83%
YTD 0.00%
2020 17.04%
2019 -74.06%
2018 -64.61%
2017 150.34%
2016 -90.09%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7352 seconds.